Circadian variations of gastrointestinal mucosal damage detected with transnasal endoscopy in apparently healthy subjects treated with low-dose aspirin (ASA) for a short period - Prevention trial, randomized double-blind placebo controlled preliminary trial

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 3, 2009, Pages 155-163

  Kawai, Takashi ^a   Yamagishi, Tetsuya ^a   Goto, Shinya ^b  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Low dose aspirin; Prevention; Rebamipide; Transnasal endoscopy

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; REBAMIPIDE;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DUODENUM ULCER; ENDOSCOPY; EPISTAXIS; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MUCOSA; HUMAN; INTESTINE ULCER; LOW DRUG DOSE; MALE; MUCOSAL DISEASE; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; STOMACH ULCER;

EID: 70350223578     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E615     Document Type: Article

References (32)

1. Khan Q, Mehta L: Relevance of platelet-independent effects of aspirin to its salutary effect in atherosclerosis-related events. J Atheroscler Thromb, 2005; 12:185-190
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J, 2002; 324:71-86
3. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH: An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med, 2003; 163:2006-2010
4. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. New Engl J Med, 2005; 352:1293-304
5. Hayden M, Pignone M, Phillips C, Multirow C: Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med, 2002; 136:161-172
6. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA: AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation, 2002; 106:388-391
7. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH: Aspirin use among US adults: Behavioral Risk Factor Surveillance System. Am J Prev Med, 2006; 30:74-77
8. Morimoto T, Nakayama M, Saito Y, Ogawa H: Aspirin for primary prevention of atherosclerotic disease in Japan. J Atheroscler Thromb, 2007; 14:159-166
9. Morimoto T, Fukui T, Lee TH, Matsui K: Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med, 2004; 117:459-468
10. Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ: Association between aspirin and upper gastrointestinal complications: systemic review of epidemiologic studies. Br J Clin Pharmacol, 2001; 52:563-571
11. Cohen MM, MacDonald WC: Mechanism of aspirin injury to human gastroduodenal mucosa. Prostaglandins Leukot Med, 1982; 9:241-255
12. Neelima G. Vallurupalli, Samuel Z. Goldhaber: Gastrointestinal complications of dual antiplatalet therapy. Circulation, 2006; 113:e665-658
13. Deepak L. Bhatt, James Scheiman, Neena S. Abraham, Elliott M. Antman, Francis K.L. Chan, Curt D. Furberg, David A. Johnson, Kenneth W. Mahaffey, Eamonn M. Quigley: ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatalet therapy and NSAID use. Circulation, 2008; 118:1894-1909
14. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, Appelman-Eszczuk S, Långström G, Naesdal J, Serrano P, Singh M, Skelly MM, Hawkey CJ: Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective dose of aspirin. Aliment Pharmacol Ther, 2005; 22:795-801
15. Daneshmend TK, Prichard PJ, Bhaskar NK, Millns PJ, Hawkey CJ: Use of microbleeding and an ultrathin endoscope to assess gastric mucosal protection by famotidine. Gastroenterology, 1989; 97:944-949
16. Venerito M, Treiber G, Wex T, Kuester D, Roessner A, Mönkemüller K, Malfertheiner P: Short-term/low-dose aspirin-induced duodenal erosions are not dependent on Helicobacter pylori infection, cyclooxygenase expression and prostaglandin E2 levels. Scand J Gastroenterol, 2008; 43:801-809
17. Johnson DA, Cattau EL, Khan A, Newell DE, Chobanian SJ: Fiberoptic esophagogastroscopy via nasal intubation. Gastrointest Endosc, 1987; 33:32-33
18. Dumortier J, Ponchon T, Scoazec JY, Moulinier B, Zarka F, Paliard P, Lambert R: Prospective evaluation of transnasal esophagogastro-duodenoscopy: feasibility and study on performance and tolerance. Gastrointest Endosc 1999; 49:285-291
19. Garcia RT, Cello JP, Nguyen MH, Rogers SJ, Rodas A, Trinh HN, Stollman NH, Schlueck G, McQuaid KR: Unsedated ultrathin EGD is well accepted when compared with conventional sedated EGD: a multicenter randomized trial. Gastroenterology 2003; 125:1606-1612
20. Kawai T, Mitazaki I, Yagi K, Kataoka M, Kawakami K, Yamagishi T, Sofuni A, Itoi T, Moriyasu F, Osaka Y, Takagi Y, Aoki T: Comparison of the effects on cardiopulmonary function of ultrathin transnasal versus normal diameter trans-oral esophagogastro-duodenoscopy in Japan. Hepatogastroenterology, 2007; 54:770-774
21. Lanas A, Scheiman J: Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin, 2007; 23:163-173
22. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, Hu WH, Lau GK, Wong WM, Yuen MF, Chan AO, Lai CL, Wong J: Lansoprazole for the prevention of ulcer complications from long-term low-dose aspirin use. New Engl J Med, 2002; 346:2033-2038
23. Murakami K, Okajima K, Uchiba M, Harada N, Johno M, Okabe H, Takatsuki K: Rebamipide attenuates indomethacin-induced gastric mucosal region formation by inhibiting activation of leukocytes in rats. Dig Dis Sci, 1997; 42:319-325
24. Kleine A, Kluge S, Peskar BM: Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci, 1993; 38:1441-1449
25. Oka S, Ogino K, Hobara T, Yoshimura S, Okazaki Y, Takemoto T, Iida Y: Effects of various mucosal protective drugs on diethyldithiocarbamate-induced antral ulcer in rats. Eur J Pharmacol, 1991; 197:99-102
26. Banan A, Fitzpatrick L, Zhang Y, Keshavarzian A: OPC-compound prevents oxidant-induced carbonylation and depolymerization of the F-action cytoskeleton and intestinal barrier hyperpermeability. Free Radical Biology and Medicine, 2001; 30:287-298
27. Dammann HG: Effect of rebamipide on aspirin-induced gastric damage: a case-control study. Eur J Gastrol & Hepatol, 1994; 6:911-915
28. Svedlund J, Sjodin I, Dotevall G: GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci, 1988; 33:129-134
29. Graham DY, Smith JL, Dobbs SM: Gastric adaptation occurs with aspirin administration in man. Dig Dis Sci, 1983; 28:1-6
30. Konturek JW, Dembinski A, Konturek SJ, Domschke W: Helicobacter pylori and gastric adaptation to repeated aspirin administration in human. J Physiol Pharmacol, 1997; 48:383-391
31. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE 3rd, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, et al: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina. J Am Cardiol, 2002; 40:1366-1374
32. Park SH, Cho CS, Lee OY, Jun JB, Lin SR, Zhou LY, Yuan YZ, Li ZS, Hou XH, Zhao HC, Udom K, Chomsri K, Comson L: Comparison of prevention of NSAIDs-induced gastrointestinal complications by rebamipide and misoprostol: A randomized, multicenter, controlled trial-STORM STUDY J Clin Biochem Nutr, 2007; 40:148-155